On October 27, 2015 Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, reported the launch of a research collaboration with Memorial Sloan Kettering Cancer Center (MSK), a premier cancer center committed to patient care and innovative research, to evaluate the immunologic and anti-tumor activity of patient tumor-specific, neoepitope-based immunotherapy (Press release, Advaxis, OCT 27, 2015, View Source [SID:1234507798]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The goal of the collaboration, titled "MINE" (My Immunotherapy Neo-Epitopes), is to use Advaxis’s Lm Technology to develop neo-epitope immunotherapies based on an individual patient’s tumor ("ADXS-NEO"). MINE will first focus on a preclinical study of Advaxis’s new construct approach to evaluate the immunologic effects and anti-tumor activity of a personalized immunotherapy in a mouse tumor model. Advaxis will use learnings from the MINE collaboration to identify and target neoepitopes using Lm Technology and later develop patient specific immunotherapy constructs that incorporate the neoepitope sequences identified in the patient’s tumor cells. Clinical studies using ADXS-NEO, to be conducted at MSK, are in development.

"Existing immunotherapies have been shown to very effectively augment tumor immunity in a subset of patients, leading to durable responses," said Jedd D. Wolchok, M.D., Ph.D., Chief of Melanoma and Immunotherapeutics Service, Department of Medicine and Ludwig Center at MSK. "However, recent advances in genome sequencing have made it possible to investigate the role of neoepitopes, or unique mutations, in an individual patient’s cancer, which may allow for the development of specific immunotherapies that generate and enhance an immune response directed against the neoepitopes contained in a patient’s tumor."

Advaxis’s Lm Technology is uniquely positioned to take advantage of the advances in genome sequencing which occurred in recent years. Lm Technology has the bandwidth to potentially target all of a patient’s immunogenic cancer neoepitopes, eliminating the need to use "predictive algorithms." This technology can enable the development of truly individualized immunotherapies that can be manufactured in a cost-effective and timely manner.

"We welcome this collaboration with MSK, a top cancer institution, which will allow us to study our clinically validated Lm Technology in a new way to deliver precision medicine by personalizing neoepitopes specific to a patient’s tumor," said David J. Mauro, M.D., Ph.D., Executive Vice President and Chief Medical Officer of Advax